AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 281 min read$FENC

Andrade Robert sold $884K of FENC

Andrade Robert (CHIEF FINANCIAL OFFICER) sold 75,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $11.78 ($0.88M total) on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Andrade Robert
Published Aug 28, 2026, 9:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FENC
Bearish
medium confidence
Mentioned
$FENC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FENCBearishLow
01

Why it matters

Provides fresh data on insider sentiment for Fennec Pharmaceuticals.

02

Market read

First disclosure of CFO's share sale; may influence short-term trading decisions.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: post-market 2026-08-27

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$FENCBearishMedium confidence
Context

CFO Andrade Robert sold 75,000 shares for $883,500 via a 10b5-1 plan.

Expected impact

Potential short-term pressure on stock price.

Evidence & confidence

Sale size is modest but involves a senior officer; market may interpret as lack of confidence.

Market effects

Sector

Minimal impact on pharmaceutical sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Sale could be routine liquidity management, not a negative signal.

Key entities

  • Officer
    Andrade Robert

    Chief Financial Officer of Fennec Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FENC insider trading history →

Related articles

AUG 13
$FENCMed

Adherex Technologies Q2 Earnings Call Highlights

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.

yahoo.com6 min
AUG 28
$LTHMedAI 8/10

Green LTF Holdings II LP sold $126.1M of LTH

Green LTF Holdings II LP sold 2,879,154 shares of Life Time Group Holdings, Inc. (LTH) at $43.80 ($126.11M total) across 3 trades on 2026-08-26. Filed jointly with GEI Capital VI, LLC (Director), Green Equity Investors Side VI, L.P. (Director), Green Equity Investors VI, L.P. (Director), Green VI Holdings, LLC (Director), Leonard Green & Partners, L.P. (Director), LGP Associates VI-A LLC (Director), LGP Associates VI-B LLC (Director), LGP MANAGEMENT INC (Director) and PERIDOT COINVEST MANAGER LLC (Director).

SEC EDGAR1 min